F S&P 500
5,251.00 +4.75 (+0.09%) F Dow Jones
39,653.00 +11.00 (+0.03%) F Nasdaq
18,290.25 +35.25 (+0.19%) E-mini Russell 2000 Index Futur
2,070.30 +2.40 (+0.12%) Petróleo
78.24 -0.02 (-0.03%) Oro
2,355.70 -19.30 (-0.81%)
IO Biotech, Inc. (IOBT)
Fuera de horario:
IO Biotech, Inc.
Ole Maaløes Vej 3
Copenhagen N
Copenhagen 2200
Denmark
45 70 70 29 80
https://www.iobiotech.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 68
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Mai-Britt Zocca Ph.D. | Founder, President, CEO, Principal Financial Officer & Director | 892.24k | N/D | 1968 |
| Mr. Devin Whittemore Smith | Secretary, General Counsel & Chief Compliance Officer | 621.8k | N/D | 1968 |
| Dr. Qasim Iftikhar Ahmad M.D. | Chief Medical Officer | 503.28k | N/D | 1971 |
| Prof. Inge Marie Svane M.D., Ph.D. | Founder & Clinical Advisor | N/D | N/D | N/D |
| Prof. Mads Hald Andersen M.D., Ph.D. | Founder & Scientific Advisor | N/D | N/D | N/D |
| Anders Ljungqvist | Founder | N/D | N/D | N/D |
| Prof. Per Thor Straten | Founder | N/D | N/D | N/D |
| Ms. Amy B. Sullivan M.B.A. | Chief Financial Officer | 391.24k | N/D | 1971 |
| Mr. Eric Faulkner M.B.A. | Chief Technical Officer | N/D | N/D | N/D |
| Mr. Daniel G. Mannix Ph.D. | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Descripción
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Gestión corporativa
La calificación ISS Governance QuickScore de IO Biotech, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
